Trial Condition(s):
Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)
Bayer Identifier:
13102
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.
Inclusion Criteria
- Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient knowledge of French or Dutch to be able to participate in the Study
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the Belgian product information
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Belgium | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Prospective open-label non-interventional, non-controlled multi observational and pharmaco-economic phase IV trial to evaluate the characteristics of patients treated for advanced renal cell carcinoma with Nexavar ® as well as effectiveness, safety and direct medical costs of Nexavar® treatment under daily-life treatment conditions
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculatedTimeframe: At 1, 3, 6 and 9 months and after one year
Additional Information
Copyright © Bayer
Powered by
